OS HR for ARIA’s Rida improved 0.92-->0.88 from the date of the ASCO abstract submission (#msg-63300650) to the cutoff for the ASCO presentation itself:
Follow-up for OS is ongoing, and the current trend favors ridaforolimus: results at the most recent data cut-off (386 OS events) showed a median OS of 21.4 months for the oral ridaforolimus group compared to 19.2 months for the placebo arm (hazard ratio=0.88, p=0.2256).
Thus, the OS HR is closing in on the 0.85 number previously posted as the threshold for what I consider a strong outcome to support the statisg data on the primary endpoint of PFS (#msg-60136247).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.